MARKET

PLX

PLX

Protalix Biother
AMEX
1.275
+0.025
+2.00%
Opening 12:21 03/28 EDT
OPEN
1.250
PREV CLOSE
1.250
HIGH
1.280
LOW
1.250
VOLUME
117.02K
TURNOVER
0
52 WEEK HIGH
3.550
52 WEEK LOW
1.205
MARKET CAP
93.14M
P/E (TTM)
12.65
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PLX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at PLX last week (0311-0315)?
Weekly Report · 03/18 11:25
Protalix BioTherapeutics Q4 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $10.49M Beat $5.80M Estimate
Protalix BioTherapeutics reports quarterly losses of $0.07 per share and sales of $10.49 million. The company missed the analyst consensus estimate of $5.80 million by 133.33%. The company reported quarterly losses for the same period last year.
Benzinga · 03/14 10:56
Protalix BioTherapeutics GAAP EPS of $0.09 misses by $0.01, revenue of $65.49M beats by $1.54M
Seeking Alpha · 03/14 10:51
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. Reports financial results for the fiscal year ended December 31, 2023. The company received regulatory approvals of Elfabrio for the treatment of adult patients with Fabry disease. Company to host conference call and webcast today at 8:30 a.m. EDT.
PR Newswire · 03/14 10:50
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Earnings Preview: Protalix BioTherapeutics
Protalix BioTherapeutics is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Analysts estimate the company will report an earnings per share of $-0.03. Last quarter the company missed EPS by $0.00 and shares are down 28.64%.
Benzinga · 03/13 19:01
Protalix BioTherapeutics FY Earnings Preview
Seeking Alpha · 03/13 16:32
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.